Substance Use Prevention for Recently Displaced Adults - SUPRA (R33) RCT (SUPRA RCT R33)
調査の概要
詳細な説明
The war in Ukraine has provoked the world's current largest humanitarian displacement: since February 2022, over 13 million people, i.e., one-third of Ukrainians, have been forced to leave their homes, resulting in nearly 6 million internally displaced persons (IDPs). War and humanitarian emergencies may exacerbate substance use, but the incidence and prevalence of unhealthy substance use in humanitarian settings, including Ukraine, are currently largely unknown. This lack of data limits the ability to tailor targeted, effective preventive substance use interventions for these mobile populations. Addressing this knowledge gap is an immense priority for Ukraine, where rates of substance use were high even prior to the Russian invasion in February 2022, and in other settings hosting large populations of IDPs, including the United States.
To determine the feasibility, acceptability, and preliminary effectiveness of the intervention among IDPs, a RCT to evaluate implementation and substance use outcomes associated with the intervention at 1 and 6 months.
The investigators hypothesize that an ACT-based intervention delivered in a humanitarian context will help displaced persons in Ukraine build skills to manage stress and prevent or reduce substance use behaviors, ultimately mitigating the onset of substance use disorders.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Karsten Lunze, MD DrPH MPH
- 電話番号:617-414-6933
- メール:lunze@bu.edu
研究連絡先のバックアップ
- 名前:Kimberly Hook, PhD MA
- メール:kmhook@hsph.harvard.edu
研究場所
-
-
-
Kyiv、ウクライナ
- Alliance for Public Health
-
コンタクト:
- Pavlo Smyrnov
- 電話番号:+380 44 490-5485
- メール:Smyrnov@aph.org.ua
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age 18 or over
- Have been displaced at least once due to Anti-Terrorist Operation (ATO) or full-scale invasion since 2014
- Self-reported use of at least one substance other than alcohol and tobacco within the past 3 months
- Ability to provide informed consent and speak Ukrainian or Russian
Exclusion Criteria:
- Self-reported diagnosis of a substance use disorder
- Inability to provide informed consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:ACT Therapy
Participants randomized to this group will receive the ACT intervention
|
The ACT group intervention will involve a mixture of didactic instruction, discussion, and experiential activities.
ACT will help internally displaced persons to manage stress and prevent or reduce substance use behaviors, ultimately mitigating the onset of substance use disorders.
|
|
アクティブコンパレータ:Attention Control
Participants in the control group will receive minimally enhanced usual care to receive treatment as usual enhanced by a health information group session.
|
Usual care will be minimally enhanced by providing participants with an educational information session that provides information on health promotion.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility of the ACT Intervention
時間枠:1 month and 6 months
|
Feasibility will be assessed using the 14-item feasibility subscales of the Applied Mental Health Research Group Implementation Measure (AMHR-IM).
Each item is rated on a 4-point scale where "0" means "not at all" and "3" means "a lot".
The overall Feasibility score is calculated as the mean (average) across all 14 completed items, where higher scores (closer to 3) reflect a higher level of perceived feasibility of the intervention.
|
1 month and 6 months
|
|
Acceptability of the ACT Intervention
時間枠:1 month and 6 months
|
Acceptability will be assessed using the 17-item acceptability subscales of the Applied Mental Health Research Group Implementation Measure (AMHR-IM).
Each item is rated on a 4-point Likert scale where "0" means "not at all" and "3" means "a lot".
The overall Acceptability score is calculated as the mean (average) across all 17 completed items, where higher scores (closer to 3) reflect a higher level of perceived acceptability of the intervention.
|
1 month and 6 months
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Karsten Lunze, MD DrPH MPH、Boston University Chobanian & Avedisian School of Medicine
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。